Ubs Group Ag Kaleido Biosciences, Inc. Transaction History

Ubs Group Ag

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$0.05 - $1.7 $23 - $795	-468 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.3 - $2.7 $13,975 - $29,025	-10,750 Reduced 95.83%	468 $1,000
Q4 2021 Feb 14, 2022	BUY	$2.39 - $6.02 $26,811 - $67,532	11,218 New	11,218 $26,000
Q3 2021 Nov 15, 2021	SELL	$5.36 - $7.99 $2,680 - $3,995	-500 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$5.82 - $8.72 $12,291 - $18,416	-2,112 Reduced 80.86%	500 $4,000
Q1 2021 May 12, 2021	BUY	$7.2 - $16.82 $18,806 - $43,933	2,612 New	2,612 $21,000
Q4 2020 Feb 11, 2021	SELL	$5.77 - $11.33 $548 - $1,076	-95 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$5.09 - $11.07 $14,883 - $32,368	-2,924 Reduced 96.85%	95 $1,000
Q2 2020 Jul 31, 2020	SELL	$4.62 - $8.01 $30,755 - $53,322	-6,657 Reduced 68.8%	3,019 $22,000
Q1 2020 May 01, 2020	SELL	$3.62 - $9.49 $15,747 - $41,281	-4,350 Reduced 31.01%	9,676 $60,000
Q4 2019 Feb 14, 2020	BUY	$5.02 - $8.87 $51,063 - $90,225	10,172 Added 263.93%	14,026 $70,000
Q3 2019 Nov 14, 2019	BUY	$6.74 - $11.3 $19,842 - $33,267	2,944 Added 323.52%	3,854 $29,000
Q2 2019 Aug 14, 2019	BUY	$11.25 - $18.1 $10,237 - $16,471	910 New	910 $11,000

2.65K

Ticker KLDO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,622,600
Description
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the tr...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.